Both of these biotechs are highly innovative companies. We are still in a bull market, but the biotech industry, as measured by the SPDR S&P Biotech ETF (an industry benchmark), hasn't been keeping up with broader equities this year. That's no reason to avoid biotech stocks -- after all, some are doing just fine. That's the case with Vertex Pharmaceuticals (VRTX -0.41%) and Sarepta Therapeutics (SRPT 0.87%). Although these drugmakers continue to perform well, both look to have plenty of upside. Let's find o ...

A downtrend has been apparent in Sarepta Therapeutics (SRPT) lately with too much selling pressure. The stock has declined 10.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicat ...

Sarepta Therapeutics, Inc. (SRPT) posted earnings of 7 cents per share in second-quarter 2024, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago period, the company posted a loss of 27 cents. The loss included depreciation and amortization expenses and stock-based compensation expenses. Adjusted earnings per share in the quarter stood at 44 cents against the year-ago period's adjusted loss of $1.01 per share. Sarepta recorded total revenues of $362.9 million, up 39% year over year. ...

For the quarter ended June 2024, Sarepta Therapeutics (SRPT) reported revenue of $362.93 million, up 38.9% over the same period last year. EPS came in at $0.07, compared to -$0.27 in the year-ago quarter. ...

Financial Data and Key Metrics Changes - For Q2 2024, the company recorded total revenues of $362.9 million, an increase of $101.7 million compared to $261.2 million in Q2 2023 [39] - Net product revenue for ELEVIDYS was $121.7 million, while the PMO franchise generated approximately $238.8 million, showing modest growth [40][41] - The company reported a GAAP net income of $6.5 million for Q2 2024, compared to a net loss of $23.9 million in Q2 2023 [41] Business Line Data and Key Metrics Changes - The Duchenne franchise generated net product revenues of approximately $361 million in Q2 2024, a 51% increase year-over-year [7] - ELEVIDYS achieved $121.7 million in net product revenue, while the PMO franchise saw revenues of roughly $239 million, indicating slight growth [10][11] - Individual net product sales included $129.8 million for EXONDYS 51, $77.4 million for AMONDYS 45, and $31.6 million for VYONDYS 53 [40] Market Data and Key Metrics Changes - The company anticipates net product revenue for 2025 to be between $2.9 billion and $3.1 billion, indicating strong market potential [9][17] - The company is experiencing robust demand from the Duchenne patient population, with significant interest in ELEVIDYS following its label expansion [12][13] Company Strategy and Development Direction - The company aims to treat the prevalent Duchenne population throughout the decade, transitioning to the incident population in 2030-2031 [9][53] - The focus remains on expanding access to ELEVIDYS and ensuring patient safety while navigating the complexities of gene therapy launches [19][20] - The company is committed to advancing its pipeline, including therapies for limb-girdle muscular dystrophy and other rare diseases [28][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the launch of ELEVIDYS, noting that the early demand signals are positive and that the company is well-prepared to meet patient needs [8][12] - The company expects moderate revenue growth in Q3 2024, with strong growth anticipated in Q4 2024 and beyond [8][17] - Management highlighted the importance of patient safety and education in the successful integration of new therapies into treatment regimens [19][20] Other Important Information - The company achieved cash flow positivity for the first time in its history and expects to maintain this status moving forward [35] - A termination of a development and supply agreement related to an adherent manufacturing process is expected to incur additional R&D expenses of approximately $55 million to $65 million [37][38] Q&A Session Summary Question: What is the actual bottleneck in the patient journey from prescription to drug administration? - Management clarified that there is no fundamental bottleneck, and the typical process from start form to infusion takes about three to five months, which is standard for such therapies [44][45][49] Question: How should the market think about the growth trajectory and peak sales for the upcoming years? - Management indicated that peak year sales will occur significantly in the back half of this decade, with a focus on treating the prevalent population throughout the decade [52][53] Question: What are the early launch data supporting the revenue guidance for 2025? - Management expressed confidence based on extensive experience with previous launches and current demand indicators, aligning with external market expectations [56][58]

The mean estimate comprises 17 short-term price targets with a standard deviation of $22. While the lowest estimate of $165 indicates a 14.8% increase from the current price level, the most optimistic analyst expects the stock to surge 63.4% to reach $235. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Sarepta Therapeutics (SRPT) closed the last trading session at ...

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Sarepta Therapeutics ...

Sarepta developed Elevidys in collaboration with Roche (RHHBY) . Both companies entered into a licensing agreement in 2019 to develop and market Elevidys. Per the agreement, Sarepta is responsible for marketing the therapy in the United States, while Roche is responsible for marketing the gene therapy outside the country. Sarepta is also eligible to receive collaboration revenues on the ex-U.S. sales made by Roche. This latest approval significantly expands the company's target market as it can increase its ...

Sarepta Therapeutics (SRPT) shares ended the last trading session 30.1% higher at $160.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% loss over the past four weeks. The label expansion is mainly supported by data from the phase III EMBARK study, announced last October. Though the study failed to achieve its primary endpoint, it achieved statistical significance on all pre-specified key secondary endpoints ...

Shares of Sarepta (SRPT) rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Elevidys is now approved to treat all DMD patients aged four years and older. While the FDA granted traditional approval for the therapy to treat ambulatory DMD patients (those who can still walk), it has granted accelerated approval for non-ambulatory patients. The label expansion is mainly supported by data fr ...